Limits...
Attenuation of lung inflammation and fibrosis in CD69-deficient mice after intratracheal bleomycin.

Yamauchi K, Kasuya Y, Kuroda F, Tanaka K, Tsuyusaki J, Ishizaki S, Matsunaga H, Iwamura C, Nakayama T, Tatsumi K - Respir. Res. (2011)

Bottom Line: Cluster of differentiation 69 (CD69), an early activation marker antigen on T and B cells, is also expressed on activated macrophages and neutrophils, suggesting that CD69 may play a role in inflammatory diseases.Lung inflammation in the acute phase (7 dpi) was investigated by differential cell counts and cytokine array analyses of bronchoalveolar lavage fluid.In addition, lung fibrotic changes were evaluated at 14 dpi by histopathology and collagen assays.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan.

ABSTRACT

Background: Cluster of differentiation 69 (CD69), an early activation marker antigen on T and B cells, is also expressed on activated macrophages and neutrophils, suggesting that CD69 may play a role in inflammatory diseases. To determine the effect of CD69 deficiency on bleomycin(BLM)-induced lung injury, we evaluated the inflammatory response following intratracheal BLM administration and the subsequent fibrotic changes in wild type (WT) and CD69-deficient (CD69-/-) mice.

Methods: The mice received a single dose of 3 mg/kg body weight of BLM and were sacrificed at 7 or 14 days post-instillation (dpi). Lung inflammation in the acute phase (7 dpi) was investigated by differential cell counts and cytokine array analyses of bronchoalveolar lavage fluid. In addition, lung fibrotic changes were evaluated at 14 dpi by histopathology and collagen assays. We also used reverse transcription polymerase chain reaction to measure the mRNA expression level of transforming growth factor β1 (TGF-β1) in the lungs of BLM-treated mice.

Results: CD69-/- mice exhibited less lung damage than WT mice, as shown by reductions in the following indices: (1) loss of body weight, (2) wet/dry ratio of lung, (3) cytokine levels in BALF, (4) histological evidence of lung injury, (5) lung collagen deposition, and (6) TGF-β1 mRNA expression in the lung.

Conclusion: The present study clearly demonstrates that CD69 plays an important role in the progression of lung injury induced by BLM.

Show MeSH

Related in: MedlinePlus

Effect of bleomycin treatment on lung fluid content in wild-type and CD69-deficient mice. Ratio of wet/dry lung weight 7 d after the instillation of BLM or PBS (sham treatment). Results are expressed as the mean (SEM) (n = 8 WT and 6 CD69-/- mice). The ratio between wet and dry lung weight is a measure of edema formation. *P < 0.01 vs. sham-treated mice. †P < 0.01 vs. WT mice.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3198935&req=5

Figure 3: Effect of bleomycin treatment on lung fluid content in wild-type and CD69-deficient mice. Ratio of wet/dry lung weight 7 d after the instillation of BLM or PBS (sham treatment). Results are expressed as the mean (SEM) (n = 8 WT and 6 CD69-/- mice). The ratio between wet and dry lung weight is a measure of edema formation. *P < 0.01 vs. sham-treated mice. †P < 0.01 vs. WT mice.

Mentions: To determine whether the CD69 deficiency affected the BLM-induced infiltration of inflammatory cells into the airways and parenchyma, we differentially counted the inflammatory cells in BALF at 7 dpi. As shown in Figure 2, the numbers of total inflammatory cells, macrophages, neutrophils, and lymphocytes in the BALF were significantly elevated in the BLM-injected mice compared to those in the PBS-injected mice (sham). Moreover, the increase in these cell populations in the BLM-induced mice was significantly attenuated in the CD69-/- mice. Intratracheally BLM-treated mice showed an inflammatory response characterized by the accumulation of water in the lungs, indicative of tissue edema. CD69 deficiency significantly reduced the lung fluid content resulting from BLM-treatment (Figure 3).


Attenuation of lung inflammation and fibrosis in CD69-deficient mice after intratracheal bleomycin.

Yamauchi K, Kasuya Y, Kuroda F, Tanaka K, Tsuyusaki J, Ishizaki S, Matsunaga H, Iwamura C, Nakayama T, Tatsumi K - Respir. Res. (2011)

Effect of bleomycin treatment on lung fluid content in wild-type and CD69-deficient mice. Ratio of wet/dry lung weight 7 d after the instillation of BLM or PBS (sham treatment). Results are expressed as the mean (SEM) (n = 8 WT and 6 CD69-/- mice). The ratio between wet and dry lung weight is a measure of edema formation. *P < 0.01 vs. sham-treated mice. †P < 0.01 vs. WT mice.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3198935&req=5

Figure 3: Effect of bleomycin treatment on lung fluid content in wild-type and CD69-deficient mice. Ratio of wet/dry lung weight 7 d after the instillation of BLM or PBS (sham treatment). Results are expressed as the mean (SEM) (n = 8 WT and 6 CD69-/- mice). The ratio between wet and dry lung weight is a measure of edema formation. *P < 0.01 vs. sham-treated mice. †P < 0.01 vs. WT mice.
Mentions: To determine whether the CD69 deficiency affected the BLM-induced infiltration of inflammatory cells into the airways and parenchyma, we differentially counted the inflammatory cells in BALF at 7 dpi. As shown in Figure 2, the numbers of total inflammatory cells, macrophages, neutrophils, and lymphocytes in the BALF were significantly elevated in the BLM-injected mice compared to those in the PBS-injected mice (sham). Moreover, the increase in these cell populations in the BLM-induced mice was significantly attenuated in the CD69-/- mice. Intratracheally BLM-treated mice showed an inflammatory response characterized by the accumulation of water in the lungs, indicative of tissue edema. CD69 deficiency significantly reduced the lung fluid content resulting from BLM-treatment (Figure 3).

Bottom Line: Cluster of differentiation 69 (CD69), an early activation marker antigen on T and B cells, is also expressed on activated macrophages and neutrophils, suggesting that CD69 may play a role in inflammatory diseases.Lung inflammation in the acute phase (7 dpi) was investigated by differential cell counts and cytokine array analyses of bronchoalveolar lavage fluid.In addition, lung fibrotic changes were evaluated at 14 dpi by histopathology and collagen assays.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan.

ABSTRACT

Background: Cluster of differentiation 69 (CD69), an early activation marker antigen on T and B cells, is also expressed on activated macrophages and neutrophils, suggesting that CD69 may play a role in inflammatory diseases. To determine the effect of CD69 deficiency on bleomycin(BLM)-induced lung injury, we evaluated the inflammatory response following intratracheal BLM administration and the subsequent fibrotic changes in wild type (WT) and CD69-deficient (CD69-/-) mice.

Methods: The mice received a single dose of 3 mg/kg body weight of BLM and were sacrificed at 7 or 14 days post-instillation (dpi). Lung inflammation in the acute phase (7 dpi) was investigated by differential cell counts and cytokine array analyses of bronchoalveolar lavage fluid. In addition, lung fibrotic changes were evaluated at 14 dpi by histopathology and collagen assays. We also used reverse transcription polymerase chain reaction to measure the mRNA expression level of transforming growth factor β1 (TGF-β1) in the lungs of BLM-treated mice.

Results: CD69-/- mice exhibited less lung damage than WT mice, as shown by reductions in the following indices: (1) loss of body weight, (2) wet/dry ratio of lung, (3) cytokine levels in BALF, (4) histological evidence of lung injury, (5) lung collagen deposition, and (6) TGF-β1 mRNA expression in the lung.

Conclusion: The present study clearly demonstrates that CD69 plays an important role in the progression of lung injury induced by BLM.

Show MeSH
Related in: MedlinePlus